Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: The ICCARRE project

FASEB Journal

Volumn 29, Issue 6, 2015, Pages 2223-2234

  Leibowitch, Jacques ^a   Mathez, Dominique ^a   De Truchis, Pierre ^a   Ledu, Damien ^a   Melchior, Jean Claude ^a   Carcelain, Guislaine ^b   Izopet, Jacques ^c   Perronne, Christian ^a   David, John R ^d  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHU PURPAN   (France)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adjusted posology; Deontology; Medical ethics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 CD8 RATIO; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS RESISTANCE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE ACTIVATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME; VERY ELDERLY; VIREMIA; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIREMIA; YOUNG ADULT;

EID: 84933555933     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-260315     Document Type: Article

References (68)

1. Leibowitch, J., Mathez, D., de Truchis, P., Perronne, C., and Melchior, J. C. (2010) Short cycles of antiretroviral drugs provide intermittent yet effective therapy: a pilot study in 48 patients with chronic HIV infection. FASEB J. 24, 1649-1655
2. Ledergerber, B., Cavassini, M., Battegay, M., Bernasconi, E., Vernazza, P., Hirschel, B., Furrer, H., Rickenbach, M., and Weber, R.; Swiss HIV Cohort Study. (2011) Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med. 12, 279-288
3. Kaulich-Bartz, J., Dam, W., May, M. T., Lederberger, B., Widmer, U., Phillips, A. N., Grabar, S., Mocroft, A., Vilaro, J., van Sighem, A., Moreno, S., Dabis, F., Monforte, A. D., Teira, R., Ingle, S. M., and Sterne, J. A.; Writing Committee for the Antiretroviral Therapy Cohort Collaboration. (2013) Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS 27, 1641-1655
4. Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D., and Siliciano, R. F. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300
5. Chun, T. W., Engel, D., Berrey, M. M., Shea, T., Corey, L., and Fauci, A. S. (1998) Early establishment of apool of latently infected, resting CD4 (+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869-8873
6. Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., and Siliciano, R. F. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727-728
7. Joos, B., Fischer, M., Kuster, H., Pillai, S. K., Wong, J. K., Böni, J., Hirschel, B., Weber, R., Trkola, A., and Günthard, H. F.; Swiss HIV Cohort Study. (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA 105, 16725-16730
8. Ho, Y. C., Shan, L., Hosmane, N. N., Wang, J., Laskey, S. B., Rosenbloom, D. I., Lai, J., Blankson, J. N., Siliciano, J. D., and Siliciano, R. F. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551
9. Siliciano, J. D., and Siliciano, R. F. (2013) HIV-1 eradication strategies: design and assessment. Curr. Opin. HIV AIDS 8, 318-325
10. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., and Singh, N. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21-30
11. Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., and Pau, A. K.; Panel on Clinical Practices for Treatment of HIV. (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137, 381-433
12. Ferguson, N. M., Donnelly, C. A., Hooper, J., Ghani, A. C., Fraser, C., Bartley, L. M., Rode, R. A., Vernazza, P., Lapins, D., Mayer, S. L., and Anderson, R. M. (2005) Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J. R. Soc. Interface 2, 349-363
13. Dybul, M., Chun, T. W., Yoder, C., Hidalgo, B., Belson, M., Hertogs, K., Larder, B., Dewar, R. L., Fox, C. H., Hallahan, C. W., Justement, J. S., Migueles, S. A., Metcalf, J. A., Davey, R. T., Daucher, M., Pandya, P., Baseler, M., Ward, D. J., and Fauci, A. S. (2001) Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc. Natl. Acad. Sci. USA 98, 15161-15166
14. American College of Physicians. (2012) ACP Ethics Manual Sixth Edition. Available at: http://www.acponline.org/running-practice/ethics/manual/manual6th.htm
15. Yazdanpanah, Y., Fagard, C., Descamps, D., Taburet, A. M., Colin, C., Roquebert, B., Katlama, C., Pialoux, G., Jacomet, C., Piketty, C., Bollens, D., Molina, J. M., and Chêne, G.; ANRS 139 TRIO Trial Group. (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin. Infect. Dis. 49, 1441-1449
16. Boyle, A., Sonecha, S., Mandalia, S., and Nelson, M. (2012) An investigation into frequency and reasons why patients switch antiretroviral therapy and which antiretrovirals are commonly implicated in toxicity. J. Int. AIDS Soc. 15(Suppl 4), 18121
17. Sauce, D., Almeida, J. R., Larsen, M., Haro, L., Autran, B., Freeman, G. J., and Appay, V. (2007) PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21, 2005-2013
18. Izopet, J., Cazabat, M., Pasquier, C., Sandres-Sauné, K., Bonnet, E., Marchou, B., Massip, P., and Puel, J. (2002) Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology 302, 393-404
19. Kesäniemi, Y. A., Tarpila, S., and Miettinen, T. A. (1990) Low vs high dietaryfiber and serum, biliary, and fecal lipids in middle-aged men. Am. J. Clin. Nutr. 51, 1007-1012
20. Kent, S. J. (2012) Loss of control of HIV viremia associated with the fat malabsorption drug orlistat. AIDS Res. Hum. Retroviruses 28, 961-962
21. Tseng, A. L., la Porte, C., and Salit, I. E. (2013) Significant interaction between activated charcoal and antiretroviral therapy leading to subtherapeutic drug concentrations, virological breakthrough and development of resistance. Antivir. Ther. (Lond.) 18, 735-738
22. Lambert-Niclot, S., Flandre, P., Valantin, M. A., Soulie, C., Fourati, S., Wirden, M., Sayon, S., Pakianather, S., Bocket, L., Masquelier, B., Dos Santos, G., Katlama, C., Calvez, V., and Marcelin, A. G. (2012) Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One 7, e41390
23. Lucas, G. M., Chaisson, R. E., and Moore, R. D. (1999) Highly active antiretroviral therapy in a largeurbanclinic: risk factors for virologicfailureand adverse drugreactions. Ann. Intern. Med. 131, 81-87
24. Glass, T. R., Rotger, M., Telenti, A., Decosterd, L., Csajka, C., Bucher, H. C., Günthard, H. F., Rickenbach, M., Nicca, D., Hirschel, B., Bernasconi, E., Wandeler, G., Battegay, M., and Marzolini, C.; Swiss HIV Cohort Study. (2012) Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. PLoS One 7, e29186
25. Wilson, I. B., Bangsberg, D. R., Shen, J., Simoni, J. M., Reynolds, N. R., Goggin, K., Gross, R., Arnsten, J. H., Remien, R. H., Erlen, J. A., and Liu, H.; Multisite Adherence Collaboration on HIV 14 Investigators. (2013) Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J. Acquir. Immune Defic. Syndr. 64, 448-454
26. Thompson, M. A., Aberg, J. A., Cahn, P., Montaner, J. S., Rizzardini, G., Telenti, A., Gatell, J. M., Günthard, H. F., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Reiss, P., Richman, D. D., Volberding, P. A., Yeni, P., and Schooley, R. T.; International AIDS Society-USA. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304, 321-333
27. Euopean AIDS Clinical Society. (2011) Clinical Management and Treatment of HIV-Infected Adults in Europe
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2014) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents/Adherence to Antiretroviral Therapy. Department of Healthand Human Services, Washington, DC. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
29. Cohen, C. J., Colson, A. E., Sheble-Hall, A. G., McLaughlin, K. A., and Morse, G. D. (2007) Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin. Trials 8, 19-23
30. Piketty, C., Weiss, L., Assoumou, L., Burgard, M., Mélard, A., Ragnaud, J. M., Bentata, M., Girard, P. M., Rouzioux, C., and Costagliola, D.; ANRS 116 SALTO Study Group. (2010) A high HIV DNA level in PBMCsatantiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J. Med. Virol. 82, 1819-1828
31. Boulassel, M. R., Chomont, N., Pai, N. P., Gilmore, N., Sékaly, R. P., and Routy, J. P. (2012) CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J. Clin. Virol. 53, 29-32
32. Fourati, S., Flandre, P., Calin, R., Carcelain, G., Soulie, C., Lambert-Niclot, S., Maiga, A., Ait-Arkoub, Z., Tubiana, R., Valantin, M. A., Autran, B., Katlama, C., Calvez, V., and Marcelin, A. G. (2014) Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J. Antimicrob. Chemother. 69, 753-756
33. Mugavero, M. J., Lin, H. Y., Willig, J. H., Westfall, A. O., Ulett, K. B., Routman, J. S., Abroms, S., Raper, J. L., Saag, M. S., and Allison, J. J. (2009) Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin. Infect. Dis. 48, 248-256
34. Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., Francioli, P., and Weber, R.; Swiss HIV Cohort Study. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353, 863-868
35. Gianotti, N., Galli, L., Racca, S., Salpietro, S., Cossarini, F., Spagnuolo, V., Barda, B., Canducci, F., Clementi, M., Lazzarin, A., and Castagna, A. (2012) Residual viraemia does not influence 1 year virological rebound in HIV-infectedpatients withHIVRNA persistently below 50 copies/mL. J. Antimicrob. Chemother. 67, 213-217
36. Charpentier, C., Landman, R., Laouénan, C., Joly, V., Hamet, G., Damond, F., Brun-Vézinet, F., Mentré, F., Descamps, D., and Yeni, P. (2012) Persistentlow-levelHIV-1RNAbetween20and50copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J. Antimicrob. Chemother. 67, 2231-2235
37. Gatell, J., Salmon-Ceron, D., Lazzarin, A., Van Wijngaerden, E., Antunes, F., Leen, C., Horban, A., Wirtz, V., Odeshoo, L., Van den Dungen, M., Gruber, C., and Ledesma, E.; SWAN Study Group. (2007) Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clin. Infect. Dis. 44, 1484-1492
38. Ghosn, J., Carosi, G., Moreno, S., Pokrovsky, V., Lazzarin, A., Pialoux, G., Sanz-Moreno, J., Balogh, A., Vandeloise, E., Biguenet, S., Leleu, G., and Delfraissy, J. F. (2010) Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir. Ther. (Lond.) 15, 993-1002
39. Giuntini, R., Martinelli, C., Ricci, E., Vichi, F., Gianelli, E., Madeddu, G., Abeli, C., Palvarini, L., Penco, G., Marconi, P., Grosso, C., Pellicano, G., Bonfanti, P., and Quirino, T. (2010) Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med. 11, 40-45
40. Hocqueloux, L., Choisy, P., Le Moal, G., Borsa-Lebas, F., Plainchamp, D., Legac, E., Prazuck, T., de la Tribonnière, X., Yazdanpanah, Y., and Parienti, J. J. (2012) Pharmacologicboosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensityscore adjusted study. PLoS One 7, e49289
41. Molina, J. M., Clumeck, N., Orkin, C., Rimsky, L. T., Vanveggel, S., and Stevens, M.; ECHO and THRIVEStudy Groups. (2014) Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Med. 15, 57-62
42. Rokx, C., Fibriani, A., van de Vijver, D. A., Verbon, A., Schutten, M., Gras, L., and Rijnders, B. J.; AIDS Therapy Evaluation in the Netherlands National Observational Cohort. (2015) Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort. Clin. Infect. Dis. 60, 143-153
43. Gantner, P., Koeppel, C., Partisani, M., Batard, M. L., Bernard-Henry, C., Cheneau, C., De Mautort, E., Priester, M., Muret, P., Sueur, C., Fafi-Kremer, S., and Rey, D. (2014) Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scand. J. Infect. Dis. 46, 838-845
44. Baril, J., Conway, B., Giguère, P., Ferko, N., Hollmann, S., and Angel, J. B. (2014) A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction. HIV Med. 15, 301-310
45. Bierman, W. F., van Agtmael, M. A., Nijhuis, M., Danner, S. A., and Boucher, C. A. (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23, 279-291
46. Arribas, J. R., Horban, A., Gerstoft, J., Fätkenheuer, G., Nelson, M., Clumeck, N., Pulido, F., Hill, A., van Delft, Y., Stark, T., and Moecklinghoff, C. (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24, 223-230
47. Mathis, S., Khanlari, B., Pulido, F., Schechter, M., Negredo, E., Nelson, M., Vernazza, P., Cahn, P., Meynard, J. L., Arribas, J., Bucher, H. C. (2011) Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One, 6, e22003
48. Guiguet, M., Ghosn, J., Duvivier, C., Meynard, J. L., Gras, G., Partisani, M., Teicher, E., Mahamat, A., Rodenbourg, F., Launay, O., and Costagliola, D.; FHDH-ANRS CO4. (2012) Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. AIDS 26, 2345-2350
49. Devereux, H. L., Youle, M., Johnson, M. A., and Loveday, C. (1999) Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13, F123-F127
50. Tseng, A., and Foisy, M. (2012) Handbook and website on HIV drug therapy. Am. J. Health Syst. Pharm. 69, 1284-1286, 1286
51. Zehnacker, L., Abe, E., Mathez, D., Alvarez, J. C., Leibowitch, J., Azoulay, S. (2014) Plasma and intracellular antiretroviral concentrations in HIV-infected patients under short cycles of antiretroviral therapy. AIDS Res. Treat. 2014, 724958
52. Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré, P., and Leibowitch, J. (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116
53. Stevenson, M., Stanwick, T. L., Dempsey, M. P., and Lamonica, C. A. (1990) HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560
54. Zhang, Z. Q., Wietgrefe, S. W., Li, Q., Shore, M. D., Duan, L., Reilly, C., Lifson, J. D., and Haase, A. T. (2004) Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 101, 5640-5645
55. Pan, X., Baldauf, H. M., Keppler, O. T., and Fackler, O. T. (2013) Restrictions to HIV-1 replication in resting CD4+T lymphocytes. Cell Res. 23, 876-885
56. Davey, R. T., Jr., Bhat, N., Yoder, C., Chun, T. W., Metcalf, J. A., Dewar, R., Natarajan, V., Lempicki, R. A., Adelsberger, J. W., Miller, K. D., Kovacs, J. A., Polis, M. A., Walker, R. E., Falloon, J., Masur, H., Gee, D., Baseler, M., Dimitrov, D. S., Fauci, A. S., and Lane, H. C. (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109-15114
57. Garćia, F., Plana, M., Vidal, C., Cruceta, A., O'Brien, W. A., Pantaleo, G., Pumarola, T., Gallart, T., Miró, J. M., and Gatell, J. M. (1999) Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13, F79-F86
58. Neumann, A. U., Tubiana, R., Calvez, V., Robert, C., Li, T. S., Agut, H., Autran, B., and Katlama, C.; Comet StudyGroup. (1999) HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 13, 677-683
59. Dybul, M., Nies-Kraske, E., Dewar, R., Maldarelli, F., Hallahan, C. W., Daucher, M., Piscitelli, S. C., Ehler, L., Weigand, A., Palmer, S., Metcalf, J. A., Davey, R. T., Rock Kress, D. M., Powers, A., Beck, I., Frenkel, L., Baseler, M., Coffin, J., and Fauci, A. S. (2004) A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J. Infect. Dis. 189, 1974-1982
60. Ananworanich, J., Nuesch, R., Le Braz, M., Chetchotisakd, P., Vibhagool, A., Wicharuk, S., Ruxrungtham, K., Furrer, H., Cooper, D., Hirschel, B., Bernasconi, E., Cavassini, M., Ebnöther, C., Fagard, C., Genné, D., Khanna, N., Perrin, L., Phanupak, P., Ubolyam, S., Vernazza, P., and Yerly, S.; SwissHIV Cohort Study. (2003) Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17, F33-F37
61. Parienti, J. J., Das-Douglas, M., Massari, V., Guzman, D., Deeks, S. G., Verdon, R., and Bangsberg, D. R. (2008) Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 3, e2783
62. Rudy, B. J., Sleasman, J., Kapogiannis, B., Wilson, C. M., Bethel, J., Serchuck, L., Ahmad, S., and Cunningham, C. K.; Adolescent Trials Network for HIV/AIDS Interventions. (2009) Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res. Hum. Retroviruses 25, 555-561
63. Reynolds, S. J., Kityo, C., Hallahan, C. W., Kabuye, G., Atwiine, D., Mbamanya, F., Ssali, F., Dewar, R., Daucher, M., Davey, R. T., Jr., Mugyenyi, P., Fauci, A. S., Quinn, T. C., and Dybul, M. R. (2010) A randomized, controlled, trialofshortcycle intermittentcompared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One 5, e10307
64. Fauci, A. S., and Marston, H. D. (2014) Ending AIDS-is an HIV vaccine necessary? N. Engl. J. Med. 370, 495-498
65. Reijers, M. H., Weverling, G. J., and Jurriaans, S., Wit, F. W., Weigel, H. M., Ten Kate, R. W., Mulder, J. W., Frissen, P. H., van Leeuwen, R., Reiss, P., Schuitemaker, H., de Wolf, F., Lange, J. M. (1998) Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: ADAM study. Lancet 352, 185-190
66. Havlir, D. V., Marschner, I. C., and Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P., Holohan, M. K., Leavitt, R., Boone, G., Richman, D. D. (1998) Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N. Engl. J. Med. 339, 1261-1268
67. Pialoux, G., Raffi, F., and Brun-Vezinet, F., Meiffrédy, V., Flandre, P., Gastaut, J. A., Dellamonica, P., Yeni, P., Delfraissy, J. F., Aboulker, J. P. (1998) A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale deRecherches sur le SIDA 072) Study Team. N. Engl. J. Med. 339, 1269-1276
68. Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J. P., Pialoux, G., Raffi, F., and Brun-Vézinet, F. (2000) Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA 283, 205-211